An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity
- 1 December 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (23), 9641-9649
- https://doi.org/10.1158/0008-5472.can-10-0527
Abstract
Overexpression of MDM4 (also known as MDMX or HDMX) is thought to promote tumorigenesis by decreasing p53 tumor suppressor function. Even modest decrease in Mdm4 levels affects tumorigenesis in mice, suggesting that genetic variants of MDM4 might have similar effects in humans. We sequenced the MDM4 gene in a series of ovarian cancer cell lines and carcinomas to identify mutations and/or single nucleotide polymorphisms (SNPs). We identified an SNP (SNP34091) in the 3′-UTR of MDM4 that creates a putative target site for hsa-miR-191, a microRNA that is highly expressed in normal and tumor tissues. Biochemical evidence supports specific miR-191–dependent regulation of the MDM4-C, but not MDM4-A, variant. Consistently, the A-allele was associated with statistically significant increased expression of MDM4 mRNA and protein levels in ovarian carcinomas. Importantly, the wild-type genotype (A/A) is more frequent (57.8% vs. 42.2% for A/C and C/C, respectively) in patients with high-grade carcinomas than in patients with low-grade carcinomas (47.2% vs. 52.5% for A/A and A/C + C/C, respectively). Moreover, A/A patients who do not express the estrogen receptor had a 4.2-fold [95% confidence interval (CI) = 1.2–13.5; P = 0.02] increased risk of recurrence and 5.5-fold (95% CI = 1.5–20.5; P = 0.01) increased risk of tumor-related death. Unexpectedly, the frequency of p53 mutations was not significantly lower in A/A patients. We conclude that acquisition of an illegitimate miR-191 target site causes downregulation of MDM4 expression, thereby significantly delaying ovarian carcinoma progression and tumor-related death. Importantly, these effects appear to be, at least partly, independent of p53. Cancer Res; 70(23); 9641–9. ©2010 AACR.Other Versions
This publication has 39 references indexed in Scilit:
- Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogeneProceedings of the National Academy of Sciences of the United States of America, 2009
- Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissuesRNA, 2008
- MDMX Promotes Proteasomal Turnover of p21 at G1 and Early S Phases Independently of, but in Cooperation with, MDM2Molecular and Cellular Biology, 2008
- MdmX Promotes Bipolar Mitosis To Suppress Transformation and Tumorigenesis in p53-Deficient Cells and MiceMolecular and Cellular Biology, 2008
- Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and DevelopmentMolecular and Cellular Biology, 2007
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheepNature Genetics, 2006
- Principles of MicroRNA–Target RecognitionPLoS Biology, 2005
- Human MicroRNA TargetsPLoS Biology, 2004
- Prediction of Mammalian MicroRNA TargetsCell, 2003